Collegium Pharma (COLL) Tops Q2 EPS by $1.43

Collegium Pharma (NASDAQ: COLL) reported Q2 EPS of $1.79, $1.43 better than the analyst estimate of $0.36. Revenue for the quarter came in at $82.9 million versus the consensus estimate of $84.77 million.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.

You May Also Be Interested In

• Nebius soars on second quarter revenue beat
• Xilio Therapeutics, Inc. (XLO) Tops Q2 EPS by 25c
• Sutro Biopharma Inc. (STRO) Misses Q2 EPS by 13c